Tempus AI Sees Huge Opportunity in Cancer Diagnostics

The recent breakthrough in personalized cancer vaccines from Moderna and Merck has sparked interest in the diagnostics work behind every dose. Analysts are now focusing on the genetic sequencing required for each patient's immune system to target specific mutations.

Every personalized cancer vaccine requires a tumor to be sequenced first, creating a recurring revenue stream per patient. Tempus AI, a genomic-sequencing firm, is well-positioned to benefit from this trend as it has partnered with Moderna and Merck for sequencing services.

Piper Sandler estimates the melanoma vaccine could generate at least $50 million in annual sequencing revenue if regulators approve it. BTIG analyst Mark Massaro projects that figure could exceed $600 million, assuming expansion into lung, bladder, and kidney cancers.